Cover Image

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer

<p><strong>Objective:</strong> To determine the effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in patients with non-small cell lung cancer.</p><p><strong>Method:</strong> This is a retrospective observational study including patients t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Amparo Burgos-San José (Author), Claudia Colomer-Aguilar (Author), Daniel Martínez-Caballero (Author), Bartomeu Massutí-Sureda (Author)
Format:	Book
Published:	Elsevier, 2021-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
by: Matteo Franchi, et al.
Published: (2022)

Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
by: Miriam Alonso-García, et al.
Published: (2022)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
by: Facchinetti F, et al.
Published: (2018)

Macular‐type cutaneous adverse reaction due to atezolizumab and pembrolizumab
by: Hitomi Sugino, et al.
Published: (2022)

Análise das notas técnicas do Núcleo de Apoio ao Judiciário da Bahia (NATJUS - BA) para os medicamentos Atezolizumabe; Nivolumabe e Pembrolizumabe.
by: Pedro Paulo Ribeiro Silva Cunha, et al.
Published: (2023)

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022)

Bullous pemphigoid in a metastatic lung cancer patient associated with nivolumab
by: Yuka Maya, MD, et al.
Published: (2020)

Atezolizumab-Induced Bell's Palsy in a Patient With Small Cell Lung Cancer
by: Asim Kichloo MD, et al.
Published: (2020)

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
by: Dongchu Zhou, et al.
Published: (2022)

The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer
by: Sarah Sharman Moser, et al.
Published: (2023)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
by: Hsin-Yu Kuo, et al.
Published: (2022)

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
by: Hyung Jun Kim, et al.
Published: (2023)

Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
by: Marcos Oro-Ayude, et al.
Published: (2020)

Atezolizumab-Induced Stevens-Johnson Syndrome in a Patient with Non-Small Cell Lung Carcinoma
by: Phatcharawat Chirasuthat, et al.
Published: (2018)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
by: Yingcheng Wang, et al.
Published: (2021)

Comparison of two‐stage and joint TGI‐OS modeling using data from six atezolizumab clinical studies in patients with metastatic non‐small cell lung cancer
by: Antonio Gonçalves, et al.
Published: (2024)

Recurrent pembrolizumab-induced mechanical small bowel obstruction in a patient with metastatic cervical cancer
by: Sha Sha, et al.
Published: (2024)

Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
by: Le AD, et al.
Published: (2017)

Regression of Multiple Melanocytic Nevi in Two Patients on Nivolumab for Metastatic Melanoma
by: Gloria Baeza-Hernández, et al.
Published: (2023)

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
by: Nanumi Han, et al.
Published: (2018)

Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis
by: Camille M Powers, et al.
Published: (2024)

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer
by: Xiaomin Wan, et al.
Published: (2021)

Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)
by: Solange Peters, et al.
Published: (2022)

Nivolumab induced vitiligo-like depigmentation in metastatic acral lentiginous melanoma
by: Disha Dabbas, et al.
Published: (2019)

Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab
by: Wataru Omata, et al.
Published: (2022)

An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab
by: Sarah G. Bell, et al.
Published: (2021)

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma
by: Anna L. Cogen, MD, PhD, et al.
Published: (2018)

Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab
by: Camélia Benhayoun, et al.
Published: (2024)

Pembrolizumab-Induced Lichen Planus on the Scalp of a Patient with Non-Small-Cell Lung Carcinoma
by: Aya Yamashita, et al.
Published: (2021)

Atezolizumab-Induced Acrodermatitis and Pustular Psoriasis in a Patient with Non-Small Cell Lung Cancer: A Rare Case Report
by: Davide Fattore, et al.
Published: (2024)

Resolution of paraneoplastic alopecia areata following nivolumab in a patient with metastatic melanoma
by: Sophia Wix, MPhil, et al.
Published: (2023)

Autoimmune hemolytic anemia during long‐term administration of nivolumab for metastatic melanoma
by: Koji Nakajima, et al.
Published: (2021)

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
by: Xuezhi Hao, et al.
Published: (2021)

Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer
by: Min Jung Geum, et al.
Published: (2021)

The prognostic value of weight and body composition changes in patients with non‐small‐cell lung cancer treated with nivolumab
by: Juliette H.R.J. Degens, et al.
Published: (2021)

Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer
by: A S Kolbin, et al.
Published: (2020)

Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer
by: Ivy Riano MD, et al.
Published: (2020)

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens
by: Li LF, et al.
Published: (2024)

Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer
by: I. S. Krysanov, et al.
Published: (2023)

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
by: Pramod Savarapu, et al.
Published: (2021)